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Background: It is possible that genes on the X chromosome are expressed differently depending of its parental
origin. The objective of this study was to determine the influence of the parental origin of the X-chromosome on
phenotypic variability, response to rhGH and on the biochemical profile of TS patients.
Methods: This was a cross-sectional multicenter correlational study carried out over three years in six Latin-American
university hospitals. Unrelated 45,X TS patients (n = 93; 18.3 ± 8.5 years)) were evaluated. A subgroup (n = 34) of the
patients were prospectively treated with rhGH over two years. DNA profiles of patients and their mothers were compared
to determine the parental origin of the retained X-chromosome through 10 polymorphic X-chromosome-STRs. The
association with clinical features, biochemical profiles and anthropometric data at the beginning and after two years of
rhGH treatment was determined.
Results: Seventy two percent of patients retained the maternal X chromosome (Xm). A trend towards significance
between maternal height and patients final height (p≤ 0.07) in 45,Xm subjects was observed. There was no correlation
between paternal height and patient height. No differences were detected between both groups in regard to
dysmorphic features, classical malformations or increase in the height-SDS after rhGH. There were higher levels of
triglycerides, total and LDL cholesterol in patients >20 years who retained the Xm.
Conclusions: The parental origin of the retained X chromosome may influence lipid metabolism in TS patients, but its
effect on growth seems to be minimal. No parental-origin-effect on the phenotypic features, associated anomalies and on
the growth response to rhGH was found in 45,X TS individuals.
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Turner syndrome (TS) is defined as the combination of
short stature, gonadal dysgenesis, typical visible somatic
dysmorphic stigmata, and urinary, cardiovascular, meta-
bolic and skeletal abnormalities associated with a missing
or structurally abnormal second sexual chromosome [1].
This disorder is one of the most common human chromo-
somal anomalies, occurring in approximately 1:2500 live
female births. More than 50% of TS patients have an ap-
parent non-mosaic 45,X karyotype and a wide and variable
spectrum of clinical features and associated complications
of TS are present even in the individuals with non-mosaic
pure 45,X karyotypes.
The absence of the second X-chromosome in TS leads
to a loss of expression of either paternally or maternally
derived genes on the X-chromosome, depending of the X
chromosome retained [2]. The haploinsufficiency of genes
that are normally expressed from two sexual chromo-
somes is the most plausible mechanism to explain the TS
phenotype. However, the absence of the second sexual
chromosome has led to the speculation that there may be
genes present on the X chromosome which are expressed
differently depending upon whether they are maternally or
paternally derived [3]. Thus, both the haploinsufficiency of
genes on the two sexual chromosomes and the parental
origin (monoallelic expression of the imprinted genes)
may play a part in the broad and variable clinical features
spectrum seen in TS. Therefore, TS could be a model for
understanding the role of genomic imprinting on the
clinical features and putative imprinted genes on the
X-chromosome.
A continuing controversy remains regarding the impact
of the retained X-chromosome on the clinical features of
TS according to their parental origin, in particular with
regards to height, deafness, cardiovascular and metabolic
abnormalities and to the growth response to rhGH. In
the context of this controversy, the current study was
performed to evaluate the effect of the parental origin of
the X-chromosome on the clinical features, auxological
data, associated complications, lipid metabolism and re-
sponse to rhGH in a group of patients with TS and a non-
mosaic 45,X karyotype.Subjects and methods
This is a cross-sectional multicenter correlational study
carried out in 6 Latin-American university hospitals over
the past three years. The study protocol was approved by
the medical ethics institutional review board of all partici-
pating hospitals (Unidad de Genetica Medica, Universidad
del Zulia; Unidad de Endocrinologia Pediatrica, Hospital
de Clínicas Caracas; Departamento de Endocrinología y
Laboratorio, Hospital de Niños de la Santísima Trinidad;
Unidad de Endocrinología, Hospital T Álvarez; Institutode Investigaciones Materno Infantil, Facultad de Medicina,
Universidad de Chile; División de Endocrinología,
Hospital Domingo Luciani; and Departamento de
Pediatría, Hospital de Especialidades Pediátricas). Initially,
unrelated prepubertal patients with TS (n = 100) examined
at our hospitals were enrolled in this study along with
their mothers. However, the study group was reduced to
93 patients after a hidden mosaicism in the second X-
chromosome was detected by molecular analysis in dupli-
cate blood samples in seven subjects. Patients included in
this study were from the following countries: Venezuela
(n = 55) Argentina (n = 29), and Chile (n = 9). The diagno-
sis of TS was based on typical clinical features and on
cytogenetic analysis. Only patients with a non-mosaic 45,
X karyotype were included and the average number of an-
alyzed metaphases was 50. A subgroup (n = 34) of the pa-
tients that fitted eligibility criteria for rhGH treatment was
analyzed both longitudinally and prospectively. We have
used the following eligibility criteria for rhGh treatment:
1) age over 2 years old; 2) girls with a height below the
third percentile in normal height curves, decreased growth
velocity and without significant spontaneous catch-up
growth; and 3) no previous administration of growth-
stimulating therapy or of estrogen replacement. Compli-
ance was determined by the clinical response to rhGH
therapy (significant increase in their linear growth and in
their growth velocity following rhGH administration). In
some of the girls, compliance was also determined by sig-
nificant increases in serial IGF-1 measurements during
rhGH therapy. With respect to parental age, chronological
age, height-SDS, weight-SDS, BMI-SDS, bone age delay,
and parental origin of retained X-chromosome, no statis-
tical difference was found between patients of different
countries at the beginning of the study. Thus, these coun-
try subgroups were pooled as one group. Written in-
formed consents for DNA sampling and for participation
in the study were obtained from parents or adult patients
before beginning the study.
Each patient was examined by two clinicians in each
center. Clinical data were collected from the patients using
a previously designed standardized checklist for TS which
included more than 100 variables and recorded. The stan-
dardized checklist will be sent upon request. Clinical
features encompassed facial dysmorphic stigmata and
ophthalmologic, auditive, thoracic, skeletal and cutaneous
signs. In addition, cardiovascular, renal metabolic and
endocrinological abnormalities were prospectively evalu-
ated. Serum fasting levels of glucose, total-, LDL-, VLDL-
and HDL-cholesterol and triglyceride concentrations were
measured in all subjects by the enzymatic method.
Measurements were performed directly in each of the 6
reference hospitals. When a patient was receiving HRT,
this was discontinued 3 months prior to assessment. Im-
aging studies performed included renal and cardiac
Table 1 Patient and parental data according to origin of
the retained X-chromosome
Xm (n = 67) Xp (n = 26) p
Patients’ height-SDS −3.8 ±1.32 −3.7 ±1.5 0.31
Maternal height SDS −1.1 ±0.9 −0.8 ±0.7 0.14
Paternal height SDS 0.8 ±0.6 0.9 ±0.8 0.75
Mid-parental height −0.9 ±0.9 −0.9 ±0.6 0.23
Values are expressed as group means ± SD, sample sizes as n = .
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of the molecular analysis.
The mean age for the whole group was 18.3 ± 8.5 years
(range 0.4-46 years). Auxological evaluation was performed
by trained physicians using standard techniques and
included measurements of weight (expressed in kg and
in standard deviation scores (SDS)), parental height, stand-
ing height expressed in cm and transformed into SDS
according to national growth chart references for each
country (patient value minus mean age- and sex-matched
control values (cm) divided by the corresponding SD
according to age) in order to evaluate all patients from
different countries. The mid-parental height was calculated
as paternal height minus 12.5 cm plus maternal height
divided by 2, then converted to SDS using national norma-
tive height data for females and males at 19 years of age.
To analyze the growth response to rhGH, anthropometric
data were evaluated at the start of rhGH therapy and every
3 months thereafter for 2 years. Growth velocities, total
height gain and differences in the increment were calcu-
lated [4]. Recombinant human growth hormone (rhGH)
was administered at a mean dose of 37 ± 5 μg/kg/day seven
days a week by subcutaneous injection for a two year
period. Body mass index (BMI) was expressed as SDS. Left
hand and wrist radiographs were assessed prior to starting
therapy and then yearly for bone age determination using
the methods of Greulich and Pyle.
Molecular analysis
Isolation, quantification and purification of genomic
DNA, selection of Short Tandem Repeats on the X-
chromosome (X-STRs), PCR amplification, and fragments
analysis are described in Additional file 1. Briefly, DNA
samples were obtained from a few drops of venous blood
placed on the filter paper from patients and their mothers.
Genomic DNA was extracted and quantitated using the
DNA IQ™ System kit (Promega, Madison, WI, USA). PCR
conditions were optimized in our laboratory using the
QIAGEN Multiplex PCR kit according Gusmao et al. and
Edelman et al. [5,6]. The X-STRs were selected due to 1)
their location on both Xp and Xq; 2) their high degree of
heterozygosity (between 66 to 82%); and 3) their high dis-
crimination power obtained in Latin-American popula-
tions, both in males (≥1 in 5 × 105) and females (≥1 in 3 ×
109), as well as high mean exclusion chance in father/
daughter duos (≥99.953%) and in father/mother/daughter
trios (≥99.999%) [5,6]. Separation and detection of the
different amplicons generated during the PCR was
performed in an ABI PRISM 310 Genetic Analyzer
(Applied Biosystems). The parental origin of the single X
chromosome was assigned as maternal when the patient
and her mother shared an allele at each of the ten loci
tested using the X-STRs decaplex. Paternal DNA was
excluded to avoid potential ethical problems.Stastical analysis
Data analysis was performed using GraphPad Prism for
Windows XP, version 4.0 (GraphPad Software, San Diego,
CA, USA). Quantitative variables are shown as mean ± SD
or median (range). The Mann–Whitney U-test was
performed to examine the possible relationship between
age, birth height and weight, height, weight, BMI, mater-
nal, paternal and mid-parental heights and the parental
origin of the X chromosome. The Kolmogorov-Smirnov
test was used to test the normal distribution of these vari-
ables and Pearson correlation coefficients were used to
assess the correlations among the various variables. To
compare the frequencies of categorical variables between
the Xp and Xm groups we performed the Fisher’s exact
test. The Wilcoxon signed ranks test was used to relate
the pre- and the on rhGH treatment patient variables. To
estimate the parental origin effect on the response to
rhGH treatment, multiple linear regression analysis was
performed with growth response to rhGh treatment pa-
rameters as the dependent variables and parental origin of
the retained X-chromosome as potentially influencing
variable. The t-test was used to compare biochemical data
between Xp and Xm patients. ANCOVA was used to
adjust for age and BMI, as covariates followed by the
Fisher protected least-significant-difference tests. Two-
sided p values were calculated for age, BMI, total choles-
terol, HDL-cholesterol, LDL-cholesterol, triglycerides and
fasting glucose. Statistical significant differences were
assumed if p < 0.05.
Results
In Table 1 we can see the patient and parental data
according to origin of the retained X-chromosome. No
significant difference between the origin of the retained
X-chromosome and height-SDS of patients was found
(p < 0.31). A stronger, but non significant correlation
(p ≤ 0.07) between final height of subjects carrying the
Xm chromosome and maternal height was found
(Table 2). There was also a trend towards significance be-
tween maternal height and patients height in the ≤ 7 years
of age group (p ≤ 0.09) who retained the Xm. However,
among the group of subjects who retained the Xp no
correlation was demonstrated at any age group. The cor-
relation observed between the patients’ height and mid-
Table 2 Correlation of patient’s height-SDS with parental height according to the retained X-chromosome at different
age groups
Age groups Maternal height Paternal height Mid-parental height
Xm = 67 Xp = 26 Xm= 67 Xp = 26 Xm= 67 Xp = 26
Neonatal r = 0.341 r = 0.282 r = 0.301 r = 0.282 r = 0.263 r = 0.287
p = 0.24 p = 0.45 p = 0.62 p = 0.39 p = 0.44 p = 0.43
≤ 7 years old r = 0.58 r = 0.405 r = 0.381 r = 0.241 r = 0.489 r = 0.375
p = 0.09 p = 0.11 p = 0.23 p = 0.43 p = 0.12 p = 0.21
Final Height r = 0.601 r = 0.598 r = 0.362 r = 0.213 r = 0.521 r = 0.421
p = 0.07 p = 0.09 p = 0.32 p = 0.52 p = 0.09 p = 0.17
Sample sizes as Xm = or Xp=; and number of measures (in brackets). Kolmogorov-Smirnov test showed no deviation from linearity (p < 0.01). Values are
correlations of patient and parental height (Pearson’s correlation coefficient) p ≤ 0.05.
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tween patients’ height and maternal height, but the statis-
tical significance was less at each age group. We found no
correlation at any age group between paternal and patients
height in the Xp group.
No significant differences in the incidence of any of the
visible somatic dysmorphic stigmata, or in urinary, cardio-
vascular, metabolic and skeletal abnormalities were ob-
served among the patients from the different countries.
Additionally, no significant differences between the sub-
jects who retained the Xm or Xp chromosome were found
in relation to the frequency of somatic stigmata or associ-
ated abnormalities (Table 3). The incidence of cardiovas-
cular anomalies was similar between the two different
genotype groups (18/67: 26.9% vs 8/26: 30.8%). Renal
anomalies were present in 16/67 (23.9%) of the patients
who retained the Xm versus 6/26 (23.1%) in those with
retained Xp. There was no statistically significant differ-
ence among the genotypes described above (p = 0.9). Simi-
lar results were found for other anomalies, including ear
and thyroid abnormalities (Table 3).
Thirty-four of our TS patients received rhGH therapy,
24 of them retained the Xm, and 10 retained the Xp. At
the beginning of therapy, there were no statistically signifi-
cant differences in baseline auxological features between
the two genotype groups. The chronological age was simi-
lar in both groups (Xm = 10.8 ± 2.8 years vs Xp = 9.9 ±
3.1 years). The height-SDS of patients was not significantly
different between those who retained the Xm (−2.81 ±
0.71) and those who retained the Xp (−2.66 ± 0.63).
Growth hormone therapy significantly (p < 0.0001) in-
creased growth velocity (cm/yr) and standing height (SDSTable 3 Associated disorders and anomalies according to the
Type Cardiac anomalies Renal anomalies Webb
Parental
origin











A/T: affected/total (%); Fisher’s exact test: ap = 0.7980; bp = 1.0, cp = 0.1547; dp = 0.78and cm) during the first (7.56 ± 1.35 cm/yr; -2.47 ± 0.65)
and second years (5.66 ± 1.51 cm/yr; -2.35 ± 0.71) in the
total group (Xm+Xp). However, these changes were not
significantly different among the patients who retained the
Xm and those who retained the Xp (p value =0.51; 0.49;
0.26; 0.54; respectively) (Table 4). Additionally, no differ-
ences in the total two-year height gain or in the increment
of height-SDS among patients with different retained
X chromosome were found (Table 4).
Pooled data from fasting serum levels of glucose, total-,
LDL-, VLDL- and HDL-cholesterol were indistinguishable
between the two genotype groups. Triglycerides, total-,
HDL- and LDL-cholesterol and fasting glucose levels were
similar in the Xm and Xp groups in subjects <20 years.
However, serum levels of triglycerides (p < 0.001), total-
(p < 0.03), and LDL-cholesterol (p < 0.04) were signifi-
cantly higher in the subjects ≥20 years who retained the
Xm chromosome, when compared to those in the the Xp
group (Table 5).
Discussion
As reported in previous studies [7-14], but with an appro-
priate sample size and with more sensitive/specific molecu-
lar analysis, we found that 2 out of 3 patients with
monosomy for 45,X retained the Xm. To explain the higher
frequency of maternal X-chromosome several hypotheses
have been proposed [15-19]. However, and we agree with
the hypothesis, given the nonviability of 45,Y cells, the rea-
son for this ratio is that women have two chances of con-
tributing to a monosomic offspring, while man has only
one. Thus, the 2:1 ratio is not consistent with a protective
effect of the maternal X-chromosome [8,9,20-22].parental origin of the retained X chromosome
ed neck Ear disorders Thyroid disorders












Table 4 Clinical and auxological data of the growth
response to rhGH according to the parental origin of the
retained X chromosome
Xm (n = 24) Xp (n = 10) P
Age at start yr 10.8 ± 2.8 9.9 ± 3.1 0.45
rhGH dose (mg/kg/day) 0,37 ±0.08 0,37 ± 0.02 0.87
Pretreatment height-SDS −2.81 ± 0.71 −2.66 ± 0.63 0.12
HV during first yr (cm/y) 7.65 ± 1.73 7.87 ± 1.1 0.51
HV during second yr (cm/y) 5.74 ± 1.57 5.59 ± 1.77 0.49
Height-SDS at first yr −2.21 ± 0.64 −2.25 ± 0.79 0.26
Δ height-SDS 0.55 ± 0.43 0.56 ± 0.41 0.54
According to SDS in relation to national growth chart references for each
country. Multiple linear regression analysis was performed with growth
response to rhGH treatment parameters as the dependent variables and
parental origin of the retained X-chromosome as potentially
influencing variable.
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Apparently, this altered metabolic status was not associ-
ated to the karyotype or to BMI. Sagi et al. demonstrated
that in their study group almost a third of the patients
exhibited high total- and LDL-cholesterol levels. These
atherogenic levels were significantly higher in the Xp than
in Xm group [9]. Previously, Van et al. in adult TS patients
and in a larger size study group demonstrated higher tri-
glycerides, total and LDL-cholesterol in the Xm group
than in the Xp groups [12]. Our study included the meas-
urement of lipid profiles in both pediatric and adult pa-
tients, trying to clarify the discrepancy found by the two
studies mentioned above. Our finding of an atherogenic
lipid profile in older patients, significantly associated with
the effect of the Xm, seems to support the hypothesis of a
significant difference between the Xm and Xp groups
which parallels the usual metabolic differences seen in
normal women (46,XmXp) and men (46,XmY) [12]. Our
findings suggests that the atherogenic lipid profile is in-
trinsic and gradually progressive in TS, as the majority of
our adult TS patients were evaluated in different stages
during both their pediatric and adult life. Therefore, the
early onset of this atherogenic lipid profile may beTable 5 Serum lipid and carbohydrate data according to the
< 20 years (n = 67)
Xm (n = 48) Xp (n = 19)
Total cholesterol (mmol/l) 175 ± 29 183 ± 35
HDL-cholesterol (mmol/l) 61 ± 15 62 ± 13
LDL-cholesterol (mmol/l) 98 ± 21 101 ± 15
Triglycerides (mmol/l) 95 ± 52 97 ± 45
Fasting glucose (mg/dl) 81 ± 9 85 ± 9
BMI 19.9 ± 1.34 20.7 ± 2.13
The means of Xm and Xp were compared by one-way ANCOVA analysis to age and
Two-sided p values were calculated for age, BMI, total cholesterol, HDL-cholesterol,
significantly different only for total cholesterol (p ≤ 0.001), and for LDL cholesterol (influenced by the retained Xm chromosome. Another ex-
planation for these findings is that lipid profiles are a
highly heritable trait and the difference in lipid levels
could be due to heritability. Performing lipid studies on
the parents of the girls with TS would help clarify whether
the difference in lipid levels is an effect of the maternal X
rather than a correlation with parental lipid profiles.
Previous studies have shown conflicting results regarding
the influence of the parental origin of the X-chromosome
on the height of TS patients [7,9,11,13-15,20-22,27,28].
These differences may be due to the fact that most of the
previous reports did not classify the patients according to
their karyotypes and that patients SDS were calculated
employing the growth reference charts of Lyon et al. [29],
which could overestimate the patients’ height. Our study
only analyzed patients with a 45,X karyotype and we used
the national growth curves of each country as a reference
to calculate the patients SDS. However, the differences
noted between studies may be due mainly to confounding
factors leading to common type I (false-positive results)
errors which may be caused by a small sample size or due
to insufficient power to generate reliable and reproducible
results. The number of patients in the present study was
quite large when compared with that of previous reports.
Several studies have suggested a positive correlation
between the final height of TS patients and the height
of their mothers and a significant correlation between
maternal height and target height in Xm patients only
[9,13,27,28]. However, studies by Hamelin et al. and
Bondy et al. found no difference in height between the
Xm and Xp groups, either during childhood or adult-
hood [11,14]. The best correlation we observed was
between final height of subjects carrying the Xm
chromosome and maternal height but this weak correl-
ation was found to vary at different age group. There-
fore, we interpret the data of the current study on the
actual statistical results as 1) there is no important
effect of the parental origin of the X-chromosome on
height, and 2) maternal height influences the final
height of TS patients regardless of the parental origin ofparental origin of the retained X chromosome
≥ 20 years (n = 48)
P Xm (n = 32) Xp (n = 16) p
0.21 199 ± 38 181 ± 41 0.03
0.76 55 ± 11 61 ± 15 0.13
0.65 105 ± 17 95 ± 21 0.04
0.61 127 ± 55 99 ± 52 0.001
0.18 91 ± 8 88 ± 10 0.38
0.54 25.1 ± 7.3 24.7 ± 6.1 0.81
BMI used as covariates, followed by Tukey’s significant-difference test.
LDL-cholesterol, triglycerides and fasting glucose, but were found to be
p ≤ 0.037) in the ≥ 20-year-group.
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data presented in the current study allows us to conclude
that the effect of maternal X-chromosome imprinting on
growth at different age groups in TS remains unclear and
if any effect exists at all it is very minimal. A possible ex-
planation for this minimal effect is that it plays a modify-
ing role on (pseudo)autosomal genes that may be
unmasked by aneuploidy 45,X or that the measurements
from the same patient are no longer independent.
A Canadian study suggested that the parental origin of
the retained X-chromosome is a factor involved in the
response to rhGH in TS, as it explained more than 50% of
the adult height gain achieved with rhGH therapy in Xm
subjects [11]. In that study, the growth response to rhGH
was slightly better in the Xm individuals (n = 26) probably
because this group had mosaic karyotypes (≈25%) with
high levels of normal cells, while the Xp group was small
(n =9) and was entirely 45,X. On the other hand, Sagi
et al. and Ko et al. found no evident differences in the
response to rhGH between Xm and Xp groups [9,21].
Similar to these latter reports, we did not find significant
differences between the Xm and Xp groups with respect
to their response to rhGH. Nevertheless, our study has
two limitations. First, the current study focused on the
short-term response to rhGH (first and second years of
rhGH therapy). The factors that influence the response in
the first year of treatment may differ totally from those
that lead to the prediction of the individuals’ final height.
Secondly, only ten patients formed our Xp group and
therefore our study may suffer from a low power to detect
mild effects that may truly exist. Small size, in particular
for the Xp group, is the major limiting factor in the com-
parison of the rhGH response according to the origin of
the retained X chromosome in all published studies
[9,11,21]. However, our findings in relation to the growth
response to rhGH in TS are a product of a study that in-
cluded a well defined group of 34 patients with a pure 45,
X karyotype, conducted in six South American academic
medical centers thus avoiding a possible selection bias or
influence of local genetic pools; and the laboratory method
is widely accepted. In addition, in our study the clinical
characterization of the response to rhGh was prospective.
Furthermore, a small sample size tends to give more im-
pressive estimates, with false-positive associations, and
unlike the Canadian study, no significant associations
(negative or positive) were found between the phenotype
variation and genotype in the current study. Recently,
in the largest study carried out to date (n = 128 (Xm) vs
n = 52 (Xp), Deverny et al. demonstrated the parental
origin of the X-chromosome did not alter the effect of
rhGH treatment [15]. Due to all these results, we propose
that the parental origin of the retained X chromosome
should not be taken into account when therapy with rhGH
in TS patients is individualized.Several studies have reported a higher incidence of
cardiac or renal anomalies, webbed neck, ocular abnor-
malities and sensorineural hearing loss according to the
retained X-chromosome [9,11-14,20-22,27]. We were,
however, unable to explain the frequency or wide and
variable difference observed in the phenotype of TS
based on the retained X-chromosome. These contradict-
ory findings may be due to the study design, small pa-
tient size, different and less sensitive methods utilized to
detect anomalies, and/or the inclusion of different kar-
yotypes in previous studies. Although cryptic mosaicism
is preferably measured in peripheral blood lymphocytes,
the possibility of cryptic mosaicism in tissues other than
peripheral blood lymphocytes which could theoretically
have altered the results, needs to be considered. The
overall frequency of abnormalities found in our study (with-
out taking into account the parental origin of the
X-chromosome) was similar to the incidence reported in
the literature. We agree with the hypothesis that it seems
unlikely on biological grounds that X-chromosome-linked
imprinted genes would be critically involved in the embry-
onic development of lymphatic, cardiovascular or renal
systems, since these are not sexually dimorphic [14,30].
Conclusions
The present study demonstrates that the parental origin of
the X chromosome is unlikely to produce imprinting effects
on visible somatic dysmorphic stigmata, urinary, cardiovas-
cular and skeletal abnormalities and on the growth re-
sponse to rhGH. The effect of maternal X-chromosome
imprinting on growth in different age group in TS remains
unclear and if any effect exists it is very minimal, suggesting
a modifying role on growth (pseudo)autosomal genes.
However, the parental origin-effect may be responsible for
the expression of the X-chromosome-linked imprinted
genes critically involved in lipid metabolism. The parental
origin of the X chromosome must therefore be considered
as a possible explanation for the significant differences in
the lipid profile between Xm and Xp groups in TS patients
with a 45,X karyotype which parallels differences usually
noted between normal women and men.Additional file
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